SG47948A1 - Compounds for the treatment of neurodegenerative disorders - Google Patents
Compounds for the treatment of neurodegenerative disordersInfo
- Publication number
- SG47948A1 SG47948A1 SG1996005610A SG1996005610A SG47948A1 SG 47948 A1 SG47948 A1 SG 47948A1 SG 1996005610 A SG1996005610 A SG 1996005610A SG 1996005610 A SG1996005610 A SG 1996005610A SG 47948 A1 SG47948 A1 SG 47948A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- neurodegenerative disorders
- compounds
- pyridineethanamine
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
Publication Number | Publication Date |
---|---|
SG47948A1 true SG47948A1 (en) | 1998-04-17 |
Family
ID=26300643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996005610A SG47948A1 (en) | 1992-04-03 | 1993-04-01 | Compounds for the treatment of neurodegenerative disorders |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0633879B1 (fr) |
JP (2) | JP3120810B2 (fr) |
KR (1) | KR100259567B1 (fr) |
CN (1) | CN1044367C (fr) |
AT (1) | ATE163925T1 (fr) |
AU (2) | AU3897693A (fr) |
CA (1) | CA2133427C (fr) |
CZ (1) | CZ288519B6 (fr) |
DE (1) | DE69317411T2 (fr) |
DK (1) | DK0633879T3 (fr) |
DZ (1) | DZ1677A1 (fr) |
ES (1) | ES2115055T3 (fr) |
FI (1) | FI105025B (fr) |
HK (1) | HK1009331A1 (fr) |
HU (1) | HU211529A9 (fr) |
IL (1) | IL105276A (fr) |
MA (1) | MA22866A1 (fr) |
MX (1) | MX9301935A (fr) |
MY (1) | MY110149A (fr) |
NO (1) | NO302170B1 (fr) |
NZ (1) | NZ251384A (fr) |
PL (1) | PL180014B1 (fr) |
RU (1) | RU2128650C1 (fr) |
SG (1) | SG47948A1 (fr) |
SK (1) | SK281258B6 (fr) |
TW (1) | TW282455B (fr) |
UA (1) | UA29437C2 (fr) |
WO (1) | WO1993020052A1 (fr) |
ZA (1) | ZA932415B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9320273D0 (en) * | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
WO2007017652A2 (fr) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Utilisation therapeutique |
EA201190064A1 (ru) * | 2008-12-24 | 2012-02-28 | Астразенека Аб | Соединения этанамина и их применение для лечения депрессии |
CN104114714A (zh) * | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
WO2015067923A1 (fr) * | 2013-11-05 | 2015-05-14 | Astrazeneca Ab | Promédicaments d'antagonistes de nmda |
CA3187140A1 (fr) * | 2020-06-23 | 2021-12-30 | Biohaven Therapeutics Ltd. | Formulations topiques de (1s)-1-phenyl-2-pyridin-2-ylethanamine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE135206T1 (de) * | 1988-08-12 | 1996-03-15 | Astra Ab | Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung |
-
1993
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active IP Right Cessation
- 1993-04-01 CA CA002133427A patent/CA2133427C/fr not_active Expired - Lifetime
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 EP EP93907975A patent/EP0633879B1/fr not_active Expired - Lifetime
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/fr active IP Right Grant
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
1998
- 1998-08-21 HK HK98110056A patent/HK1009331A1/xx not_active IP Right Cessation
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
AU610036B2 (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants | |
IL110204A0 (en) | Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders | |
WO1993000094A3 (fr) | Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine | |
ZA928158B (en) | Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof. | |
SG47948A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
EP0626162A3 (fr) | Lit pour malades. | |
CA2135709A1 (fr) | Derives de melatonine servant au traitement des troubles du sommeil | |
EP0592903A3 (fr) | Utilisation du ancrod pour la préparation de médicaments pour le traitement de la restenosis. | |
CA2135710A1 (fr) | Derives de melatonine servant au traitement des troubles de synchronisation | |
HRP931016A2 (en) | Thienothiazin derivatives, process for the preparation and application thereof | |
ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
AU6581294A (en) | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders | |
ZA949347B (en) | 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production. | |
EP0583136A3 (en) | Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders | |
IL89901A0 (en) | Strobilurine derivatives | |
AU3084992A (en) | 1,4-dihydropyridines for use in the treatment of dermatosis | |
GB2270313B (en) | 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof | |
AU7183298A (en) | Melatonin derivatives for use in treating desynchronization disorders | |
GR920100423A (el) | Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος. | |
ZA934785B (en) | 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof. | |
ES1023651Y (es) | "barandilla de cama, perfeccionada" | |
ZA932062B (en) | Indole and indazole derivatives, for the treatment and prophylaxis of cerabral disorders, their preparation and their use | |
IL100396A0 (en) | Medicaments for the treatment of irradiation damages | |
HU9603287D0 (en) | Pharmaceutical composition, use thereof and process for producing the active component |